As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Tocilizumab (TCZ) for Severe COVID-19

Clinical Trial Title: 
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of TCZ in patients with severe COVID-19 pneumonia.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mariam Aziz, MD
Clinical Trial Protocol Description: 

The purpose of this study is to evaluate TCZ in combination with standard of care in hospitalized patients with severe COVID-19 pneumonia. Randomized participants will receive one infusion of TCZ 8mg/kg.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have signed informed consent form (if capable of giving consent), or, when the patient is not capable of giving consent, by his or her legal/authorized representative.
  • Are at least 18 years of age at time of signing the informed consent form.
  • Are hospitalized with COVID-19 pneumonia confirmed per a positive PCR of any specimen (e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan.
  • Have SpO2 <=93% or PaO2/FiO2 <300 mmHg.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Contact Name: 
If you or your family member is hospitalized at Rush, please speak with the attending physician about your interest.